Vivos Therapeutics (NASDAQ:VVOS) reported quarterly losses of $(0.49) per share which missed the analyst consensus estimate of $(0.41) by 18.07 percent. This is a 22.5 percent decrease over losses of $(0.40) per share from the same period last year. The company reported quarterly sales of $6.783 million which beat the analyst consensus estimate of $4.686 million by 44.73 percent. This is a 75.73 percent increase over sales of $3.860 million the same period last year.